The metabotropic glutamate receptor 5 is involved in numerous central nervous system disorders. New ways of targeting this receptor for therapeutic benefits involve designing compounds which bind specific areas within the receptor such that unique receptor outcomes can be achieved. My thesis focused on characterising these compounds, what they are able to do, and how they interact with the target receptor.